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Abstract 
Purpose: The NSABP Trial B‑31 and NCCTG Trial N9831 (B‑31/N9831 trials, Romond et al. in N Engl J Med 353:1673–
84, 2005. doi:10.1056/NEJMoa052122; Perez et al. in J Clin Oncol 32:3744–52, 2014. doi:10.1200/JCO.2014.55.5730) 
established the efficacy of adjuvant trastuzumab for patients with HER2‑positive early stage breast cancer. We aimed 
to estimate the overall survival (OS) and relapse‑free survival (RFS) of HER2‑positive non‑metastatic breast cancer 
patients treated with adjuvant trastuzumab in a clinical practice setting in the United States.
Methods: Adult women initiating adjuvant trastuzumab within 1 year of breast cancer surgery were identified in the 
health claims database of the US Department of Defense (01/2003–12/2012). OS and RFS unadjusted rates at 4 and 
6 years after the first trastuzumab treatment following the breast cancer diagnosis were estimated from Kaplan–Meier 
analyses.
Results: The study sample included 3188 women followed for a median of 3.3 years after trastuzumab initiation and 
treated continuously with trastuzumab for a median of 12 months. The OS rates (95 % confidence intervals) at 4 and 
6 years were 90.0 % (88.6–91.2) and 87.1 (85.3–88.6), respectively. The corresponding RFS rates were 75.8 % (74.0–77.5) 
and 72.7 (70.7–74.7), respectively. The OS and RFS rates at 6 years reported in the B‑31/N9831 trials were 89.8 and 
81.4 %, respectively.
Conclusions: OS rates estimated in this study were in range with those estimated in the B‑31/N9831 trials, while RFS 
rates were lower. However, patients in the B‑31/N9831 trials were younger and possibly had fewer comorbidities than 
patients in the current study; these differences were not adjusted for in the crude OS and RFS analyses.
Keywords: HER2‑positive breast cancer, Trastuzumab, Relapse, Overall survival
© 2016 Gallagher et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Most patients with breast cancer in developed countries 
are diagnosed in the early stages of disease (National 
Cancer Institute 2014; Sant et  al. 2003; Allemani et  al. 
2013; Walters et al. 2013) and undergo tumor-removing 
surgery, followed by adjuvant chemotherapy and/or tar-
geted therapies against specific overexpressed receptors 
(van Herk-Sukel et  al. 2013; National Comprehensive 
Cancer Network 2015). Approximately 20 % of the breast 
cancers are HER2-positive (Parise et  al. 2009) and have 
higher risk of cancer relapse and overall poor prognosis 
(Esteva and Hortobagyi 2004; Esteva et  al. 2002; Parkin 
et  al. 2002). In 2006, the FDA approved trastuzumab, 
a monoclonal antibody against the HER2 receptor, as 
adjuvant treatment for HER2-positive breast cancer. 
The approval was based on the results of the landmark 
National Surgical Adjuvant Breast and Bowel Project 
Trial B-31 and the North Central Cancer Treatment 
Group Trial N9831 (B-31/N9831trials), which have 
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shown that adding trastuzumab to adjuvant chemother-
apy reduces the relapse risk by half and improves patient 
survival (Valabrega et al 2007; Romond et al. 2005; Perez 
et  al. 2014). Subsequent clinical trials reached simi-
lar conclusions (Romond et  al. 2005; Perez et  al. 2014; 
Gianni et  al. 2011; Slamon et  al. 2011; Fountzilas et  al. 
2014; Joensuu et al. 2006; Burstein et al. 2012). However, 
clinical trials often exclude patients with various comor-
bidities (Van de Water et  al. 2014; Thürmann 2009), 
leading to estimates that might not always be generaliz-
able to the general patient population (Thürmann 2009; 
Rothwell 2005). The effectiveness of trastuzumab as adju-
vant treatment for HER2-positive breast cancer has also 
been studied in observational studies (Zurawska et  al. 
2013; Webster et al. 2012; Peterson et al. 2014; Palmieri 
et al. 2011; Jensen et al. 2012; Inwald et al. 2014; Hayashi 
et  al. 2013; Bonifazi et  al. 2014; Vici et  al. 2014). How-
ever, these studies faced important challenges: although 
claims-based studies had large samples, they lacked accu-
rate measures of patient clinical characteristics, includ-
ing cancer relapse (Zurawska et  al. 2013; Webster et  al. 
2012; Palmieri et al. 2011; Kirby et al. 2010); on the other 
hand, observational hospital-based studies included 
detailed clinical information, but were of limited sam-
ple size (Jensen et  al. 2012; Inwald et  al. 2014; Bonifazi 
et al. 2014) and may have had limited representativeness 
(Zurawska et al. 2013; Peterson et al. 2014; Palmieri et al. 
2011; Hayashi et al. 2013; Vici et al. 2014). Furthermore, 
to our knowledge, only one of these observational studies 
was US-based (Hayashi et al. 2013).
The current study aimed to estimate the overall survival 
(OS) and the relapse-free survival (RFS) of patients with 
HER2-positive non-metastatic breast cancer treated with 
adjuvant trastuzumab in a US clinical setting and to com-
pare this information with that observed in the pivotal 
B-31/N9831trials. To this end, an algorithm to identify 
breast cancer relapses in administrative claims data was 
developed and validated against clinical data extracted 
from a US breast cancer registry.
Methods
Data sources
The study used US Department of Defense (DOD) de-
identified patient data, covering records from 01/01/2003 
to 12/31/2012, obtained from the Military Health System 
(MHS). MHS contains comprehensive health-related 
data (inpatient and outpatient healthcare service records, 
prescription records, and demographic information) on 
over 9.5 million beneficiaries, including DOD service 
members, retirees, and their dependents (Guide for DoD 
Researchers on Using MHS Data 2012). Data were col-
lected from the MHS Data Repository (MDR) claims and 
clinical database, which includes the Defense Enrollment 
Eligibility Reporting System (DEERS), and the DOD 
Automated Central Tumor Registry (ACTUR) (see Addi-
tional file 1: Supplemental Methods).
Selection of study samples
Adult women receiving trastuzumab alone or in com-
bination with other drugs as adjuvant therapy for non-
metastatic breast cancer were selected from the MDR 
database based on criteria described in Fig.  1 (study 
sample). Because ACTUR records contain clinical infor-
mation on breast cancer relapse, the subset of patients 
from the study sample that had records in the ACTUR 




The study outcomes were OS and RFS following tras-
tuzumab initiation after breast cancer diagnosis (index 
trastuzumab, either adjuvant or neoadjuvant). OS and 
RFS were analyzed in the study sample and the registry 
sub-sample using time-to-event methods; event time 
was defined as the time between the index trastuzumab 
and death from any cause for OS, and relapse or death 
from any cause for RFS. Patients’ observation peri-
ods were censored if they reached the end of the study 
period (12/31/2012) or lost continuous healthcare cover-
age without a relapse and/or death event. Date of death 
was extracted from DEERS via the MDR. An algorithm 
was developed (described below) to identify relapses in 
claims data.
OS and RFS rates at 3, 4, 5 and 6 years after index tras-
tuzumab were extracted from the Kaplan–Meier survival 
curves for the study sample and registry sub-sample. The 
Kaplan–Meier survival curves from the B-31/N9831tri-
als were extracted for comparison purposes using the 
GetData Graph Digitizer software  (Fedorov 2014) from 
Perez et al. (2014) and Romond et al. (2012).
Relapse algorithm: definition and validation
The algorithm developed to identify relapses in claims 
data was adapted from previously published algorithms 
(Chubak et al. 2012; Cheng et al. 2012) to the specifics of 
adjuvant trastuzumab treatment in non-metastatic breast 
cancer (see Additional file  1: Supplemental Methods). 
The patient follow-up was divided in two periods: Period 
1, corresponding to the recommended 52-week trastu-
zumab treatment course (Genentech 2014) (after exclud-
ing temporary interruptions in trastuzumab use due to 
recovery from surgery and/or gaps of <90 days between 
trastuzumab infusions); and Period 2, corresponding to 
the remaining follow-up. Four indicators were used to 
identify relapses in the algorithm: (1) ≥2 independent 
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diagnoses of secondary neoplasm (see Fig.  1 for defini-
tion) that were <60 days apart, either in Period 1 or 2; (2) 
chemotherapy restart in Period 1 after a gap of ≥90 days 
in treatment; (3) chemotherapy or trastuzumab restart 
at any time in Period 2; and (4) hormonal therapy initia-
tion in Period 2 for patients who did not use hormonal 
therapy in Period 1. In some rare cases, these four indi-
cators may signal the presence of a new primary cancer 
(i.e., new cancer that is not a metastasis of the breast can-
cer). To avoid counting new primary cancers as breast 
cancer relapses, the four indicators above were discarded 
if they were preceded by a new primary cancer diagno-
sis (i.e., ICD-9-CM 140.x-209.x, excluding codes for 
breast cancer and/or secondary neoplasm). Additionally, 
indicators based on one chemotherapy or trastuzumab 
treatment were discarded if they were not followed by 
second infusion/injection/prescription fill within 30 days 
of the chemotherapy or trastuzumab restart. The relapse 
date corresponded to the date of the earliest observed 
indicator.
This algorithm was applied to the claims records of 
the patients in the registry sub-sample and its results 
were compared with the known relapse status recorded 
in ACTUR (Additional file 1: Table S1). Three validation 
statistics were computed: (1) the percentage of patients 
in the registry sub-sample for whom the claims-based 
algorithm correctly classified the patients’ relapse status; 
(2) the sensitivity of the claims-based algorithm, defined 
as the probability of correctly identifying a true (registry-
based) relapse; and (3) the specificity of the claims-based 
algorithm defined as the probability of correctly identify-
ing a true non-relapse.
Fig. 1 Sample selection flowchart. Note The following international classification of diseases, ninth revision, clinical modification (ICD‑9‑CM) codes 
were used to identify female breast cancer: 174.x for primary female breast cancer and codes 196.x‑199.x for secondary neoplasm, excluding 196.0, 
196.1, 196.3 and 198.2, which may be used to indicate locally advanced breast cancer
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Other statistical analyses
Patient characteristics were described for the study sample 
and the registry sub-sample; because the registry sub-sam-
ple was a subset of the study sample, no statistical compar-
isons were conducted between the study sample and the 
registry sub-sample. All analyses used a two-sided p-value 
of 0.05 to determine statistical significance. All analyses 
were performed with SAS v.9.3 (Cary, NC) software.
Results
Patient characteristics
The study sample included 3188 patients, observed for a 
median of 3.3 years after the index trastuzumab. Mean age 
was 62.1 years (median 63.0) and mean Charlson comor-
bidity index (CCI) was 4.2 (median 3.0). The most com-
mon comorbidities were hypertension, deficiency anemias, 
valvular heart disease, diabetes, chronic pulmonary dis-
ease, hypothyroidism, and depressive disorders (Table 1). 
Following breast cancer diagnosis, 54.8 % of patients had 
breast-removing surgery and 45.2 % had breast-conserving 
surgery. Before initiating adjuvant trastuzumab, 58.0 % of 
patients received radiation therapy and 8.7 % received neo-
adjuvant trastuzumab. The median duration of continu-
ous adjuvant trastuzumab treatment was 12 months. For 
73.5 % of patients, trastuzumab was initiated ≤6 months 
post-diagnosis (data not shown). The most common adju-
vant regimens in the study sample were TCH-like (28.4 %) 
and ACTH-like (24.2  %) regimens, trastuzumab mono-
therapy (19.4  %), and trastuzumab–taxane combinations 
(14.3 %) (Additional file 1: Table S2).
The registry sub-sample included 624 patients. Mean 
age was 54.3  years (median 54.0) and mean CCI was 
3.7 (median 3.0). Common comorbidities in the registry 
sub-sample included hypertension and deficiency ane-
mias (Table  1). Most patients in the registry sub-sam-
ple initiated trastuzumab as adjuvant therapy (92.0  %), 
58.8  % had breast-removing surgery, 41.2  % had breast-
conserving surgery, and 68.4 % had radiotherapy prior to 
the initiation of adjuvant trastuzumab (Table 1). Among 
patients with available information, 84.8 % had stage 0-II 
breast cancer and 52.9 % of patients had grade 3 cancer. 
The mean tumor size was 28.5 mm (median 20.0 mm).
Relapse algorithm validation
Relapse status was correctly identified in the registry sub-
sample in >90  % of cases. The claims-based algorithm 
had 89.7 % sensitivity and 90.1 % specificity (Table 2).
Description of the relapses identified in the study sample
The algorithm identified 564 (17.7 %) relapses in the study 
sample. Of these, 216 (38.3  %) occurred within a year 
of the first adjuvant trastuzumab infusion, 279 (49.5  %) 
occurred within 1–3  years, and 69 (12.2  %) occurred 
>3  years later. Among the patients who relapsed within 
a year of first adjuvant trastuzumab, 30.5 % deaths were 
observed over a median follow-up of 2.1  years; among 
those who relapsed within 1–3 years, there were 34.4 % 
deaths over 1.7 years; finally, among those who relapsed 
>3 years after the first adjuvant trastuzumab, there were 
20.3 % deaths over 1.5 years.
OS and RFS
In the study sample, the unadjusted OS rates were 
93.2  % (95  % CI 92.1–94.2  %) at 3  years, 90.0  % (88.6–
91.2) at 4 years, 88.5 % (86.9–89.8) at 5 years, and 87.1 % 
(85.3–88.6) at 6  years; in the registry sub-sample, these 
rates were 96.3  % (94.3–97.7), 93.7 (91.0–95.6), 92.6  % 
(89.6–94.8), and 92.2 % (89.1–94.5), respectively (Fig. 2a); 
finally, the unadjusted OS rate at 6  years in the B-31/
N9831trials (Perez et  al. 2014) was 89.8  % (Perez et  al. 
2014; Romond et al. 2012).
In the study sample, the unadjusted RFS rates were 78.8 
(77.1–80.3) at 3 years, 75.8 % (74.0–77.5) at 4 years, 73.9 % 
(72.0–75.7) at 5  years and 72.7  % (70.7–74.7) at 6  years; 
in the registry sub-sample these rates were 85.5 % (82.2–
88.2), 83.5 % (80.0–86.5), 81.4 % (77.5–84.7), and 80.4 % 
(76.3–83.9), respectively (Fig.  2b); finally, the unadjusted 
RFS rate at 6  years in the B-31/N9831trials (Perez et  al. 
2014) was 81.4 % (Perez et al. 2014; Romond et al. 2012).
Discussion
Because clinical trials recruit patients based on specific 
selection criteria that may differ from physicians’ treat-
ment decisions in clinical practice, it is important to 
measure treatment patterns and outcomes in a large clin-
ical setting and see how they compare to those measured 
in clinical trials. In this retrospective observational study 
of a large sample of American women with non-meta-
static HER2-positive breast cancer receiving adjuvant 
trastuzumab, a claims-based algorithm was developed to 
identify breast cancer relapses. The algorithm was vali-
dated against known relapse status recorded in ACTUR 
and found to perform with high specificity (90.1 %) and 
sensitivity (89.7  %). When applied to the study sample, 
the algorithm estimated OS rates that were generally 
similar to those observed in the landmark analysis of the 
B-31/N9831.trials (Fig. 2a; at 6 years 87.1 % in the current 
study versus 89.8 % in the B-31/N9831 trials) (Perez et al. 
2014), although the RFS rates in the current study were 
slightly lower than those reported in the B-31/N9831tri-
als (Fig. 2b; at 6 years 72.7 % in the current study versus 
81.4 % in the B-31/N9831 trials) (Perez et al. 2014).
Differences in patient characteristics between the current 
study and the B-31/N9831 trials may explain the observed 
OS and RFS variations. Patients in the B-31/N9831 tri-
als were generally younger than those in the current 
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Table 1 Characteristics of the study sample versus registry sub-sample at the initiation of trastuzumab treatment
Study sample Registry sub-sample
N = 3188 N = 624
Demographic characteristicsa
 Ageb [years; mean ± SD (median)] 62.1 ± 12.7 [63.0] 54.3 ± 11.6 [54.0]
 Geographic region [N (%)]
  West 771 (24.2) 165 (26.4)
  Northeast 607 (19.0) 151 (24.2)
  Southeast 791 (24.8) 117 (18.8)
  Central 688 (21.6) 103 (16.5)
  Other 85 (2.7) 51 (8.2)
  Unknown 246 (7.7) 37 (5.9)
 Trastuzumab initiation [N (%)]
  Trastuzumab initiated as neoadjuvant therapyc 277 (8.7) 50 (8.0)
  Trastuzumab initiated as adjuvant therapyd 2911 (91.3) 574 (92.0)
 Type of surgery prior to adjuvant trastuzumab [N (%)]
  Breast‑removing 1746 (54.8) 367 (58.8)
  Breast‑conserving 1442 (45.2) 257 (41.2)
  Radiation therapy prior to the first adjuvant trastuzumab [N (%)] 1849 (58.0) 427 (68.4)
Comorbiditiese (>5 % prevalence)
 Charlson comorbidity index (Quan et al. 2005)f (mean ± SD [median]) 4.2 ± 2.3 [3.0] 3.7 ± 2.0 [3.0]
 Physical comorbidities (Elixhauser et al. 2004)g [N (%)]
  Valvular disease 616 (19.3) 65 (10.4)
  Peripheral vascular disorder 203 (6.4) 11 (1.8)
  Hypertension, uncomplicated 1681 (52.7) 233 (37.3)
  Hypertension, complicated 218 (6.8) 21 (3.4)
  Other neurological disorders 184 (5.8) 15 (2.4)
  Chronic pulmonary disease 563 (17.7) 65 (10.4)
  Diabetes without chronic complications 595 (18.7) 74 (11.9)
  Diabetes with chronic complications 176 (5.5) 17 (2.7)
  Hypothyroidism 542 (17.0) 75 (12.0)
  Rheumatoid arthritis/collagen vascular diseases 166 (5.2) 23 (3.7)
  Obesity 371 (11.6) 64 (10.3)
  Fluid and electrolyte disorders 400 (12.5) 74 (11.9)
  Deficiency anemia 755 (23.7) 147 (23.6)
  Psychoses 163 (5.1) 20 (3.2)
 Mental comorbidities (American Psychiatric Association 2013)h [N (%)]
  Depressive disorders 502 (15.7) 85 (13.6)
  Anxiety disorder 437 (13.7) 85 (13.6)
  Trauma‑ and stressor‑related disorders 135 (4.2) 49 (7.9)
  Sleep‑wake disorders 390 (12.2) 68 (10.9)
  Substance‑related and addictive disorders 348 (10.9) 60 (9.6)
Cancer characteristics (recorded in cancer registry)
 Breast cancer stagei [N (%)]
  Stage 0 – 1 (0.2)
  Stage I – 260 (41.7)
  Stage II – 268 (42.9)
  Stage III – 85 (13.6)
  Stage IV – 3 (0.5)
  Missing – 7 (1.1)
 Tumor size
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Table 1 continued
Study sample Registry sub-sample
N = 3188 N = 624
  Mean size ± SD [median] (mm) – 28.5 ± 49.6 [20.0]
  Missing [N (%)] – 33 (5.3)
 Tumor type [N (%)] –
  Infiltrating duct carcinoma NOS—invasive – 454 (72.8)
  Infiltrating ductal carcinoma—invasive – 40 (6.4)
  Infiltrating duct carcinoma NOS – 18 (2.9)
  Infiltrating duct and lobular carcinoma—invasive – 30 (4.8)
  Inflammatory carcinoma—invasive – 11 (1.8)
  Lobular carcinoma NOS—invasive – 12 (1.9)
  Infiltrating duct mixed with other types—invasive – 10 (1.6)
  Carcinoma NOS—invasive – 8 (1.3)
  Other (<1 % each) 41 (6.6)
 Tumor histologic grade [N (%)] –
  Grade 1 – 30 (4.8)
  Grade 2 – 205 (32.9)
  Grade 3 – 330 (52.9)
  Grade 4 – 4 (0.6)
  Missing – 55 (8.8)
 Lymph node status [N (%)] –
  No regional lymph node involvement or isolated tumor cells – 324 (51.9)
  Some lymph node involvement – 272 (43.6)
  No regional lymph node involvement, but isolated tumor cells – 11 (1.8)
  Missing – 17 (2.7)
a All demographic characteristics were measured as of the index date, defined as the date of the first trastuzumab
b Age groups were based on year of birth
c Neoadjuvant therapy was defined as the initiation of trastuzumab alone or in combination with other drugs prior to the breast surgery. By design, patients treated 
with neo-adjuvant trastuzumab re-initiated trastuzumab following breast surgery
d Adjuvant trastuzumab therapy was defined as treatment with trastuzumab alone or in combination with other drugs within 1 year of the breast cancer surgery
e Comorbidities and risk factors were measured during the 365 days prior to index trastuzumab
f The Charlson comorbidity index (CCI) score includes two points for the cancer diagnosis. Please see corresponding reference
g Only comorbidities with >1 % prevalence in both the study sample and registry sub-sample are presented. Please see corresponding reference
h Only comorbidities with >1 % prevalence in both the study sample and registry sub-sample are presented. Please see corresponding reference
i The charts of 120 patients with missing cancer stage in the Automated Central Tumor Registry (ACTUR) were pulled from the US Department of Defense (DOD) 
military facilities that followed the patients and were individually reviewed by EB to assign a stage; for 3 patients in this group the pathological report was not 
available in the patient chart, so the stage was determined clinically; for 7 patients there was not enough information in the patient chart, so the cancer stage remains 
missing (for patients who receive care in both military and civilian facilities, only the patient charts from the military facilities were available for review)
Table 2 Validation of the algorithm used to identify relapses in claims data
Relapses identified in the ACTUR (cancer registry) Relapse algorithm validation 
statistics
Relapse No relapse Total
Relapses identified in the claims data with the claims based algorithm




85 90.1 % relapses correctly identified
 No relapse False negative True negative 539 89.7 % sensitivity
N = 3 N = 536 90.1 % specificity
 Total 29 595 624
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study sample and registry sub-sample (Additional file  1: 
Table S3). However, the age difference is expected to have 
impacted the observations from the current study more in 
terms of associated age-related comorbidities and poten-
tial tolerability issues (Freedman et al. 2014) than in terms 
of the intrinsic prognostic value of age on treatment out-
comes. While prior studies have shown that younger age is 
associated with poorer breast cancer prognosis (Freedman 
et  al. 2014), further research revealed that the molecular 
subtypes of the cancer in question (e.g., HER2-positive) 
drove this effect of age (Anders et  al. 2011), with no age 
correlation being observed in HER2-positive patients (Par-
tridge et al. 2013). In addition to age differences, patients in 
the B-31/N9831 trials also tended to have a lower comor-
bidity profile, as the B-31/N9831 trials excluded patients 
with significant cardiac diseases, congestive heart failure, 
or uncontrolled hypertension. Finally, all patients in the 
trastuzumab arm of the B-31/N9831 trials were treated 
with ACTH-like treatment regimens, while patients with 
ACTH-regimens represented only one quarter of the cur-
rent study’s sample (Romond et al. 2005; Perez et al. 2014).
When analyzing RFS in the registry sub-sample, which 
was more comparable to the B-31/N9831trials (Perez 
et  al. 2014) sample in terms of age, comorbidity profile, 
and treatment regimens (35.1 % of the patients in the reg-
istry sub-sample were treated with ACTH-like regimens, 
data not shown), the estimates of RFS were more similar: 
the RFS at 6 years was 80.4 % for the registry sub-sample 
versus 81.4 % (Perez et al. 2014) in the B-31/N9831 trials 
sample (Perez et al. 2014).
Fig. 2 Overall survival and relapse‑free survival a in clinical setting versus the B‑31/N9831 trials (data from Perez et al. JCO 2014 (Perez et al. 2014) 
were reproduced with author permission). a Overall survival. b Relapse‑free survival
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The findings of the current study were, however, very 
similar to those of the HERA trial (Gianni et  al. 2011), 
which reported 4-year OS rate of 89.3  % and RFS rate 
of 78.6  % among 1703 surgically-treated patients with 
HER2-positive early stage invasive breast cancer who 
were assigned to receive 1-year adjuvant trastuzumab 
after completion of ≥4 cycles of neoadjuvant and/
or adjuvant chemotherapy. As in the current study, 
patients in the trastuzumab arm of the HERA trial were 
exposed to a variety of neo(adjuvant) therapies prior to 
the initiation of trastuzumab, with only 26  % receiving 
neo(adjuvant) chemotherapy with anthracyclines and 
taxanes (i.e., ACTH-like regimens) (Gianni et  al. 2011). 
Despite the fact that the trastuzumab-treated patients in 
the HERA trial had lower RFS rates than that of the tras-
tuzumab-treated patients in the B-31/N9831 trials (Perez 
et al. 2014) and the BCIRG 006 trial (Slamon et al. 2011), 
their RFS rate at 4 years was significantly higher than that 
of the control chemotherapy-only arm of the HERA trial 
(72.2 %, p < 0.0001) (Gianni et al. 2011). Based on these 
findings, it can be hypothesized that some of the patients 
not treated with standard trastuzumab-based regimens 
may have poorer outcomes, either because these treat-
ments are less effective than the standard trastuzumab-
based treatments or because of underlying conditions 
that prevent them from receiving the standard treatment.
Observational studies that attempted to estimate OS 
and RFS in different clinical settings in the US (Hayashi 
et al. 2013), UK (Webster et al. 2012; Palmieri et al. 2011), 
Canada (Zurawska et al. 2013; Peterson et al. 2014), Ger-
many (Inwald et al. 2014), Italy (Bonifazi et al. 2014; Vici 
et al. 2014), and Denmark (Jensen et al. 2012) have shown 
a large variation in RFS for trastuzumab-treated patients 
with HER2-positive non-metastatic breast cancer, with 
3-year RFS rates ranging from 79.4  % (Bonifazi et  al. 
2014) to 90.3 (Webster et al. 2012), and 4-year rates rang-
ing from 60  % (Hayashi et  al. 2013) to 75.0  % (Bonifazi 
et  al. 2014). Notwithstanding differences that could be 
driven by variations in methodology, patient characteris-
tics, or care provided by different healthcare systems, the 
RFS estimates from this study were within the previously 
reported ranges.
In this study we observed proportions of patients who 
had mastectomy (55 %; the benchmark proposed by the 
America College of Surgeons/National Accreditation 
Program for Breast Centers for the general population 
of patients with breast cancer is <50  % (American Col-
lege of Surgeons 2014)) or received adjuvant trastuzumab 
as monotherapy (20  %) that were slightly higher than 
expected. These findings may be explained by the over-
all breast cancer profile of the study sample that may 
be worse than that of the overall population of patients 
with non-metastatic breast cancer. Indeed, all patients 
included in the current study received adjuvant trastu-
zumab following breast cancer (i.e., were HER2-positive), 
and a large proportion had large tumors of >2 cm, which 
make breast conservation surgery more difficult (48 % of 
registry sub-sample, where tumor size information was 
available). Also, many of the patients treated with adju-
vant trastuzumab monotherapy received neoadjuvant 
chemotherapy/targeted therapy prior to surgery (49.9 % 
among those treated with trastuzumab monotherapy 
versus 13.8 % only in the full study sample) and/or with 
hormonal therapy prior to the initiation of trastuzumab 
(18.6 vs. 8.6  %). Interestingly, the patients treated with 
adjuvant trastuzumab monotherapy also had very high 
rates of mastectomy, comparable to those observed in 
the B-31/N9831 trials (63.1 % among those treated with 
trastuzumab monotherapy vs. 61.4 % in the B-31/N9831 
trials (Perez et al. 2014)). These findings suggest that the 
patients treated with adjuvant trastuzumab monotherapy 
may have had a different breast cancer profile or different 
treatment preferences.
The strengths of this study include the large, nation-
ally representative patient sample, the relatively long fol-
low up (median follow-up of 3.3 years), and the use of a 
validated customized claims-based algorithm to identify 
relapses among breast cancer patients treated with adju-
vant trastuzumab. Of note, the true specificity of our 
relapse algorithm is likely to be higher than that reported 
in the current study, because patients that transfer from 
military to civilian healthcare facilities are lost to regis-
try follow-up, leading to an underestimation of relapses 
in ACTUR.
This study was also subject to several limitations. First, 
general limitations of claims data include possible inac-
curacies in coding diagnoses, procedures, or pharmacy 
claims. Second, because patient-level data from the B-31/
N9831trials (Perez et  al. 2014) is not publicly available, 
no adjustments were made for patient characteristic dif-
ferences when comparing the findings from the current 
study versus those of the B-31/N9831 trials; therefore, 
RFS variability among studies may be due to this factor. 
Third, although the relapse algorithm performed well, 
misclassification of some relapses may have occurred 
if treatment-based relapse indicators reflected unusual 
individual treatment patterns rather than the initiation 
of a treatment post-relapse. For example, or a transient 
decline in the left ventricle ejection fraction may result 
in gaps of >90  days in trastuzumab treatment (with-
out relapse). Military families move duty stations every 
few years and transfer of care from one medical facil-
ity to another could cause gaps in trastuzumab treat-
ment (without relapse). Such an occurrence could have 
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resulted in a lower a RFS estimate in the current study. 
Finally, despite our efforts to exclude all patients with 
metastatic breast cancer at baseline, some patients with 
metastatic breast cancer may have been included in the 
study sample. However, only 0.5 % of the patients in the 
registry sub-sample had stage IV breast cancer at diag-
nosis, suggesting such occurrences are rare in the claims 
data as well (stage IV cases were not excluded from the 
registry sub-sample to maintain the consistency with the 
claims-based study sample).
Conclusion
This descriptive retrospective study of claims and registry 
data found that the OS and RFS of HER2-positive breast 
cancer patients treated with trastuzumab in a clinical 
practice setting were similar to those previously observed 
in the B-31/N9831 trials and other randomized and 
observational studies. The findings from this US based 
study suggest that adjuvant trastuzumab is an effective 
treatment option across many patients with non-meta-
static breast cancer.
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